Author: Mark Newman

Share

Endocrine Society and Keystone Symposia Announce Series of Joint Meetings

The Endocrine Society and Keystone Symposia are partnering to hold a series of joint translation scientific meetings that connect foundational (or basic) science with clinical practice across oncology, cardiometabolism, and diabetes with the aim of supporting a full bench-to-bedside and back research cycle. Keystone Symposia contributes deep connections to basic scientists and a robust infrastructure...
Share

Partnering for Progress: Industry’s Role in Endocrinology

How the Endocrine Society’s Corporate Liaison Board fosters collaboration, fuels innovation, and advances patient care The Endocrine Society (the Society) strives to foster an interdisciplinary community of those practicing, researching, and innovating in endocrinology. Industry is an important site of innovation in endocrinology, and the Society’s Corporate Liaison Board (CLB) plays a pivotal role in...
Share

Pharma Friday – June 5, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent Trial On May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo...
Share

ACROFAST Findings: Personalized Care for Acromegaly Wins on Both Health and Budget

A precision-medicine protocol for treating acromegaly can slash healthcare costs by 22% while more than doubling a patient’s chances of reaching hormonal remission, according to an economic analysis of the ACROFAST clinical trial. “Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study,” a Spanish study recently published in the...
Share

Leaping Off the Page: The Continuing Evolution of Endocrine News

A Q&A with Executive Editor Mark A. Newman about the exciting next step for the Endocrine Society’s flagship member magazine, Endocrine News. June will mark a historical milestone for Endocrine News magazine as it fully transitions to an online-only publication. The magazine’s Executive Editor, Mark A. Newman, has been leading the publication since 2013 and...
Share

Heroin Adulterated with Diabetes Medication Triggers Life-Threatening Medical Emergencies

Medical researchers have identified a dangerous and deceptive trend in the illicit drug market after two nondiabetic patients were admitted to intensive care with life-threatening hypoglycemia following heroin use. The cases, occurring years apart but linked by the same rare clinical presentation, reveal that heroin supplies are being contaminated with glipizide, a potent prescription medication...
Share

Glucocorticoid Management in Patients with Classic Congenital Adrenal Hyperplasia with Crinecerfont

Patients with classic adrenal hyperplasia (CAH) may be able to reduce their glucocorticoid (GC) doses with crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, according to two studies recently published in The Journal of Clinical Endocrinology & Metabolism. Neurocrine Biosciences, Inc. funded the studies, and the company is marketing crinecerfont as CRENESSITY®. The two papers...